BIO-key Shares Suspended from Nasdaq, Move to OTC Markets
Event summary
- BIO-key's shares will be suspended from Nasdaq effective May 12, 2026, and will move to OTC markets starting May 13, 2026.
- The suspension is due to failure to meet Nasdaq's $1 minimum closing bid price requirement for 10 consecutive days and delayed filing of its Annual Report on Form 10-K for 2025.
- BIO-key implemented a 1-for-10 reverse stock split on April 30, 2026, to comply with Nasdaq's bid price requirement, but the timing did not meet the 10-day extension requirement.
- The company plans to request a hearing before a Nasdaq Hearings Panel to restore its Nasdaq listing.
- BIO-key expects 50% revenue growth and profitability in the first half of 2026, despite the listing suspension.
The big picture
BIO-key's suspension from Nasdaq highlights the challenges small-cap companies face in maintaining compliance with exchange listing standards. The company's strategic focus on biometric authentication and identity management positions it in a growing market, but its ability to navigate regulatory hurdles will be critical for long-term success. The move to OTC markets could impact its visibility and liquidity, making it essential to monitor its progress in regaining Nasdaq listing and achieving financial milestones.
What we're watching
- Regulatory Compliance
- Whether BIO-key can successfully appeal the Nasdaq suspension and restore its listing.
- Financial Performance
- The pace at which BIO-key achieves its projected 50% revenue growth and profitability in the first half of 2026.
- Market Dynamics
- How the move to OTC markets will affect liquidity and investor confidence in BIO-key.
Related topics